Novo EVP: Negotiations can begin now
Following approval of diabetes combo Xultophy and announcement of a list price, the head of Novo Nordisk’s US business can start negotiating with payers, who might be looking to play the company off against its rival Sanofi. “We won’t necessarily navigate based on what Sanofi decides,” says Jakob Riis.
BY STEFAN SINGH KAILAY
Novo Nordisk is not targeting a broad launch of its newly approved combination product Xultophy when it is commercialized in the US next year, but will rather go for a more narrow patient population. This is according to the head of the pharma group’s US business, Jakob Riis.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Welcome news for Novo as diabetes combo wins US approval
For abonnenter
Zealand's big money dreams can finally come true
For abonnenter
